company background image
PRTC logo

PureTech Health NasdaqGM:PRTC Stock Report

Last Price

US$29.80

Market Cap

US$759.6m

7D

-0.4%

1Y

4.6%

Updated

15 Jun, 2024

Data

Company Financials +

PureTech Health plc

NasdaqGM:PRTC Stock Report

Market Cap: US$759.6m

PRTC Stock Overview

Engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States.

PRTC fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Rewards

Risk Analysis


PureTech Health plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for PureTech Health
Historical stock prices
Current Share PriceUK£29.80
52 Week HighUK£34.00
52 Week LowUK£17.08
Beta0.98
1 Month Change3.90%
3 Month Change16.50%
1 Year Change4.63%
3 Year Change-41.68%
5 Year Changen/a
Change since IPO-22.60%

Recent News & Updates

Recent updates

PureTech Health: Repeat What Works

Mar 23

PureTech Health jumps 9.3% on takeover speculation

Oct 06

PureTech GAAP EPS of -$0.10, revenue of $7.03M

Aug 25

Shareholder Returns

PRTCUS BiotechsUS Market
7D-0.4%0.02%1.2%
1Y4.6%6.7%20.6%

Return vs Industry: PRTC underperformed the US Biotechs industry which returned 7.4% over the past year.

Return vs Market: PRTC underperformed the US Market which returned 20.5% over the past year.

Price Volatility

Is PRTC's price volatile compared to industry and market?
PRTC volatility
PRTC Average Weekly Movement8.8%
Biotechs Industry Average Movement10.4%
Market Average Movement5.8%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.9%

Stable Share Price: PRTC has not had significant price volatility in the past 3 months.

Volatility Over Time: PRTC's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201590Bharatt Chowrirawww.puretechhealth.com

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders.

PureTech Health plc Fundamentals Summary

How do PureTech Health's earnings and revenue compare to its market cap?
PRTC fundamental statistics
Market capUS$759.63m
Earnings (TTM)-US$65.70m
Revenue (TTM)US$3.33m

228.1x

P/S Ratio

-11.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PRTC income statement (TTM)
RevenueUS$3.33m
Cost of RevenueUS$96.24m
Gross Profit-US$92.90m
Other Expenses-US$27.21m
Earnings-US$65.70m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.24
Gross Margin-2,789.94%
Net Profit Margin-1,972.88%
Debt/Equity Ratio24.8%

How did PRTC perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.